Within the KRAS G12R mutated group, patients with co-occurring PI3K mutations had numerically shorter OS compared to patients with cancers without PI3K mutations (19.4 vs. 24.2 months, P = .17), but had similar PFS (12.2 vs. 12.6 months, P = .83) with first-line systemic therapies (Fig. 3B, 3E). The gene discussed is KRAS; the disease is cancer.